Artiva Biotherapeutics Inc (ARTV) is not a strong buy for a beginner, long-term investor at this time. Despite recent price gains and a bullish technical setup, the stock's financial performance is weak, with no revenue growth, negative net income, and declining EPS. Additionally, there are no significant positive catalysts or trading signals to justify immediate investment.

Technical Analysis

The technical indicators show a bullish trend with MACD positively expanding and moving averages in a bullish order (SMA_5 > SMA_20 > SMA_200). However, the RSI is at 91.064, indicating the stock is overbought, which could lead to a short-term pullback. Key resistance levels are at 5.349 and 5.79, while support levels are at 3.925 and 3.484.

Positive Catalysts

The appointment of Thad Huston as CFO, with extensive experience in pharmaceuticals and biotechnology, could improve operational efficiency and financial strategies.

Neutral/Negative Catalysts

The company's financials remain weak with no revenue growth, negative net income, and declining EPS. Additionally, the stock is overbought, which may lead to a price correction.

Financial Performance

In Q3 2025, the company reported no revenue growth (0% YoY), a net loss of -$21.53M (improved by 23.21% YoY), and a decline in EPS to -0.88 (-4.35% YoY). Gross margin dropped to 0, down 100% YoY.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for trend analysis or analyst ratings.

4 Analyst Rating

Wall Street analysts forecast ARTV stock price to rise

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 5.820

Low

Averages

18.67

High

Current: 5.820

Low

Averages

18.67

High

Wedbush

Outperform

maintain

$18 -> $23

AI Analysis

2025-10-17

Reason

Wedbush

Price Target

$18 -> $23

AI Analysis

2025-10-17

maintain

Outperform

Reason

Wedbush raised the firm's price target on Artiva Biotherapeutics to $23 from $18 and keeps an Outperform rating on the shares. The firm notes the company announced refractory rheumatoid arthritis as the lead indication for AlloNK and announced FDA Fast Track Designation, with pivotal development possible as early as 2026 pending regulatory discussions. Importantly, the development program will feature low-dose lymphodepletion to maximize B cell depletion while minimizing adverse impacts among this patient population.

H.C. Wainwright

Emily Bodnar

Buy

initiated

$12

2025-06-11

Reason

H.C. Wainwright

Emily Bodnar

Price Target

$12

2025-06-11

initiated

Buy

Reason

H.C. Wainwright analyst Emily Bodnar assumed coverage of Artiva Biotherapeutics with a Buy rating and $12 price target. The company's primary asset, AB-101, a nongenetically modified natural killer cell therapy being evaluated in various B-cell driven autoimmune diseases in combination with anti-CD20 monoclonal antibodies has potential to establish itself as a safe, efficacious, and outpatient-accessible treatment, the analyst tells investors in a research note. The firm sees significant share upside potential if initial safety and translational data in B-cell driven autoimmune diseases delivered by the end of 2025 and longer follow-up efficacy data in the first half of 2025 from the company's various Phase 1/2 studies are positive.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ARTV

Unlock Now

ARTV Should I Buy

ARTV Should I Buy

Should You Buy Artiva Biotherapeutics Inc (ARTV) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch